Kornimate/medical-research-clean huggingface dataset:
cgmis 48-hour feasibility study

Conditions: Type1diabetes

Summary: this is a single center, single arm non-randomized study of 48-hour cgmis wear duration incorporating two meal-challenge tests to explore the performance of a single insertion combined glucose-sensing insulin delivery cannula.


Eligibility criteria:
inclusion criteria: * type 1 diabetes, present for at least 6 months. if there is lack of clarity regarding the type of diabetes, the pi will make the final decision based on medical records. * age 18-75 * currently using a tandem t-slim or medtronic 523/723 or newer series insulin pump to treat their diabetes. * hgb a1c between 5.8 and 10% * willingness to follow all study procedures and to attend all clinic visits. * willingness to sign informed consent and hippa documents. exclusion criteria: * need for mri/ct/diathermy during study participation * current use of hydroxyurea * history of chronic kidney disease * inability to read pump or cgm display due to reduced visual acuity * history of unstable ischaemic heart disease or myocardial infarction within the last 3 months. * history of chronic liver disease * active infection such as hiv or hepatitis * anemia defined by hct at least 4 percentage points below lower limit of the reference range * dementia, schizophrenia or other untreated mental illness * chronic substance abuse * chronic alcohol abuse * seizure disorder * major surgical operation within 30 days prior to screening * history of bleeding disorder or treatment with anticoagulants. * allergy to acrylate-based skin adhesives * ongoing use of an investigational drug or device * female of childbearing potential who is pregnant or intending to become pregnant * diabetic ketoacidosis or hypoglycemia requiring hospitalization within the last 6 months * insulin resistance as defined by insulin requirement of more than 200 units per day * use of glucose-lowering medications other than insulin * need for uninterrupted treatment with acetaminophen * any other physical or mental condition judged by the pi as being exclusionary.
improving college students' mental help-seeking intention during the covid-19 pandemic

Conditions: Help-Seeking Behavior; Mental Health Issue

Summary: this study aimed at testing the effectiveness of a longitudinal intervention in increasing college students' intention to seek mental help during the pandemic.

this study aimed at testing the effectiveness of a longitudinal intervention in increasing college students' intention to seek mental help during the pandemic. a four-armed randomized controlled experiment was conducted to compare two self-persuasion methods against two control conditions. assessments took place at baseline (t0), post-first treatment (t1), post-second treatment (six weeks, t2), and ten-week follow-up (t3). the results showed that the intervention significantly increased students' help-seeking intention, attitude, and efficacy at different time points. it also reduced mental help-seeking-related stigma after the first task.

Eligibility criteria:
inclusion criteria: * 18 years old or older * full-time undergraduate students * had more than a moderate amount of mental distress exclusion criteria: * under 18 years old * not full-time undergraduate students * had less than a moderate amount of mental distress

Keywords: mental help-seeking covid-19 college students self-persuasion
measuring distress in prosthetic joint infection using a standardized metric: crutch pathway pilot.

Conditions: Prosthetic Joint Infection

Summary: the purpose of this study is to determine whether patients being treated for prosthetic joint infections (pji) experience distress during the course of their treatment and how distress influences various aspects of their lives. wvu expects to enroll approximately 12 subjects. patients identified as scoring ≥4 on the distress thermometer at the two-week follow-up visit will be offered the opportunity to participate in the novel crutch pathway. once enrolled, you will meet virtually with a mental health provider. the mental health provider will complete a 30-minute intake visit where he will review your distress thermometer scoring, discuss contributing factors to current distress level, and assess for psychiatric comorbidities.


Eligibility criteria:
inclusion criteria: * ability to speak and read english, and cognitively sound. patients scheduled for revision of total hip or knee arthroplasty will be categorized as septic or aseptic revisions. patients identified as scoring ≥4 on the dt at the two-week follow-up visit. exclusion criteria: * patients younger than 18 or older than 89, patients unable to speak and/or read english, and patients who are not able to understand and answer questions asked on surveys. elective primary total hip or knee arthroplasty, hemiarthroplasty, unicompartmental knee arthroplasty.
air leak test in pediatric intensive care unit

Conditions: Respiratory Distress; Upper Airway Obstruction

Summary: respiratory distress by upper airway obstruction (uao) is the primary etiology of extubation failure in children hospitalized in pediatric intensive care unit (picu). this complication may require various invasive therapeutic which increase morbi-mortality and length of hospital stay. cuff leak test (clt) measured prior extubation to predict post-extubation uao has been widely used in adult. the test compared expired tidal volume with cuff inflated and cuff deflated in order to predict uao. despite its frequent use in picu, his predictive value to predict uao in children is still poorly documented. therefore, we conducted the first multicentric, prospective study to evaluate the clt as a predictor of post-extubation uao in critically ill children. the primary objective is to assess the effectiveness of clt in predicting severe respiratory distress by uao within 48 hours of extubation in a critically ill children.


Eligibility criteria:
inclusion criteria: 1. ≥ 2 day to \< 18 years of age, 2. ventilated through a cuffed endotracheal tube, 3. expected duration of mechanical ventilation ≥ 24 hours, 4. having a cuff leak test prior extubation, 5. placed on the assist control setting during clt, 6. no opposition from parents or patient exclusion criteria: 1. receiving mechanical ventilation via a tracheostomy, 2. unplanned extubation, 3. patient with long-term non-invasive ventilation (niv), 4. history of upper airways pathology, 5. surgery of upper airways less than 1 month old, 6. limitations of medical care in place, 7. parents or patient opposition, 8. already been included in this study, 9. not affiliated with social security.
livalo acute myocardial infarction study (lamis)

Conditions: Acute Myocardial Infarction

Summary: this study is performed to observe the incidence of major cardiovascular events in korean patients with ami after giving pitavastatin 2mg and 4mg longer than 1 year.


Eligibility criteria:
inclusion criteria: * patients with stemi, nstemi * patients satisfying at least one of the followings 1. patients with ldl-c ≥ 130 mg/dl 2. patients with ldl-c ≥ 100 mg/dl who are regarded as required cholesterol lowering therapy by the investigator 3. patients taking statin are required continuous cholesterol lowering therapy * patients satisfying at least two of the followings 1. the change of ischemic ecg 2. ck, ck-mb, troponin-i increased more than two times 3. the symptom of acs exclusion criteria: 1. patients with in-stent restenosis after pci or coronary artery bypass 2. patients with cardiogenic shock 3. patients with severe heart failure (left ventricular ejection fraction is less than 30%) 4. patients who are taking cyclosporine 5. patients who experienced hypersensitivity to pitavastatin 6. patients under dialysis treatment 7. patients who are participating other clinical trials 8. patients who can not stop taking concomitant drugs 9. pregnant or lactating women or suspected pregnancy 10. patients who are regarded as ineligible for this study by the investigator

Keywords: hydroxymethylglutaryl-coa reductase inhibitors
effects of chronic ozone exposure on lung function

Conditions: Lung Diseases; Lung Diseases, Obstructive; Chronic Obstructive Pulmonary Disease

Summary: to determine the effects of chronic ozone exposure on lung function in young men and women.

background: a large part of the u.s. population is exposed to ambient ozone (o3) concentrations that are associated with acute respiratory health effects; however, little is known about the effects on human respiratory health of long-term exposure to such ambient concentrations. chronic exposure of non-human primates to high concentrations of o3 are associated with pathologic changes in the centriacinar region of the lung that are similar to changes observed in young cigarette smokers. this is the first detailed epidemiologic study of the effects of chronic exposure to an air pollutant based on individual estimates of lifetime exposure and controlled exposure data. the study tests a specific toxicologic model in humans that has relevance for chronic respiratory disease and explores mechanisms of effects. design narrative: the study tested the hypothesis that, in humans, there was an exposure-response relationship between the amount of chronic exposure to ambient o3 and measures of lung function that reflected changes in the centriacinar region of the human lung (fef25-75); and this relationship was not seen with measures of more proximal airway function (fev1). first-year uc berkeley students, ages 18-21 yrs, who were lifelong residents of the los angles basin, (high o3) and the san francisco bay area, (low o3) were studied. lifetime exposure to ambient o3 was estimated with methods developed by the investigators that combined questionnaire and ambient o3 data. lung function was assessed with maximum expiratory flow-volume curves. students were studied after 4-6 months of low ambient o3 exposure and immediately after 2-3 months of exposure to summertime o3. students from each area who were at the upper and lower tails of the fef25-75 distribution underwent two controlled o3 exposures (seasonal as above) followed by bronchoalveolar lavage/biopsy to evaluate relationships between measures of inflammation, injury/repair and oxidant induced damage/repair and fef25-75. regression was used to evaluate relationships between lifetime o3 exposure and lung function, adjusted for past and family respiratory history, allergy history, home characteristics, exposure to environmental tobacco smoke and particle air pollution and no2. the study completion date listed in this record was obtained from the "end date" entered in the protocol registration and results system (prs) record.

Eligibility criteria:
no eligibility criteria
diabetic retinopathy and oct-a changes post-cataract surgery

Conditions: Cataract; Diabetic Retinopathy; Macular Edema Due to Diabetes Mellitus

Summary: the purpose of this study is to use optical coherence tomography angiography (oct-a) to compare retinal vasculature after uncomplicated cataract surgery in patients with and without diabetic retinopathy.

patients undergoing cataract surgery who provided informed consent were enrolled in the study. there were three comparison groups: control, diabetic retinopathy (dr) and diabetic macular edema (dme) groups. optical coherence tomography angiography (oct-a) scans measuring retinal thickness, vessel density, perfusion density, and foveal avascular zone were obtained at baseline and postoperative week one, month one and month three.

Eligibility criteria:
inclusion criteria: * all patients at uptown eye specialists undergoing uneventful cataract surgery who have provided informed consent to the study. exclusion criteria: * other ocular co-morbidities such as axial length \ 25.0 mm, previous ocular surgeries, previous history of uveitis, previous ocular trauma, cornea pathologies or glaucoma, intraocular pressures over 22 mmhg * in groups 1 and 2: previous retinal laser treatments * oct-a signal strength \< 6 * use of multifocal intraocular lens * second eye (if first eye recruited) * in group 1: no diabetes mellitus as past medical history

Keywords: optical coherence tomography angiography
screening for atrial fibrillation, after ischemic stroke

Conditions: Atrial Fibrillation; Stroke

Summary: the aim of the study is to assess the incidence of patients suffering from ischemic stroke or transient ischemic attacks who have underlying asymptomatic paroxysmal atrial fibrillation. patients who have suffered an ischemic stroke or transient ischemic attack, without a history of atrial fibrillation, are planned to be included. starting within 14 days of the ischemic stroke, participating patients are asked to perform 10 second ecg recordings using a handheld ecg device twice daily (mornings and evenings) during 30 days. these recordings are transmitted via telephone to a secure encrypted internet site. within these 30 days the participants also perform an ambulatory 24 hour holter recording. handheld ecg recordings are evaluated continuously. in case of atrial fibrillation the patient is informed and offered treatment with anti coagulant medication (warfarin). the investigation is a comparison between 24 hour continuous ecg recordings and short intermittent ecg recordings twice daily over a longer time period to determine which method is the best to detect atrial fibrillation in this patient group. hypothesis: short intermittent ecg recordings over a longer time period is more efficient, compared with continuous 24 hour ecg recordings, in detecting silent paroxysmal af in patients with an ischemic stroke and without a history of atrial fibrillation.


Eligibility criteria:
inclusion criteria: * no previously diagnosed atrial fibrillation. * acute ischemic stroke or transient ischemic attack verified by computed tomography or clinical diagnosis using the national institute of health stroke score within 14 days of enrollment. * ability to understand study instructions both verbal and written. * ability to perform and transmit ecg recordings according to study design. exclusion criteria: * previously diagnosed atrial fibrillation. * hemorrhagic stroke * low compliance * pacemaker carrier

Keywords: silent paroxysmal atrial fibrillation stroke tele ecg
combination chemotherapy in treating patients with extensive stage small cell lung cancer

Conditions: Lung Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. it is not yet known whether combination chemotherapy with or without epirubicin and cyclophosphamide is more effective in treating patients with extensive stage small cell lung cancer. purpose: randomized phase iii trial to compare the effectiveness of combination chemotherapy with or without epirubicin and cyclophosphamide in treating patients who have extensive stage small cell lung cancer.

objectives: i. compare the overall survival and survival without recurrence of patients with extensive stage small cell lung cancer after receiving cisplatin and etoposide with or without epirubicin and cyclophosphamide. ii. compare the relative dose and intensity of cisplatin and etoposide between the two groups of patients. iii. compare the complete and objective response rate and quality of life of these patients. iv. compare the toxic effects of these 2 regimens in these patients. outline: this is a randomized, multicenter study. patients are randomized to one of two treatment arms. arm i: patients receive etoposide iv on days 1 and 3 and cisplatin iv on day 2. arm ii: patients receive etoposide and cisplatin as in arm i, plus epirubicin iv on day 1 and cyclophosphamide iv on days 1 and 3. treatment is repeated in both arms every 28 days for up to 6 courses. patients who achieve a partial or complete response receive cerebral and/or thoracic radiotherapy. patients with residual tumor may receive oral etoposide for 3 of every 4 weeks. patients are followed every 3 months. projected accrual: a total of 216 patients will be accrued for this study within 2.5 years.

Eligibility criteria:
disease characteristics: histologically proven extensive stage small cell lung cancer extends beyond hemithorax and supraclavicular lymph nodes pleural effusions allowed bidimensionally measurable disease bone marrow metastases allowed no symptomatic cns metastases or carcinomatous meningitis patient characteristics: age: 18 to 75 performance status: 0-2 life expectancy: not specified hematopoietic: neutrophil count at least 2,000/mm3 platelet count at least 100,000/mm3 hepatic: bilirubin no greater than 1.5 times normal renal: creatinine less than 1.24 mg/dl or creatinine clearance greater than 60 ml/min cardiovascular: no cardiac insufficiency no uncontrolled cardiac disease lvef greater than 50% or echo greater than 30% other: not pregnant fertile patients must use effective contraception no psychoses no active infection no loss of weight greater than 10% during the last 3 months no other malignancy except nonmelanomatous skin cancer or stage i cervical cancer prior concurrent therapy: biologic therapy: no prior or concurrent immunotherapy chemotherapy: no prior or other concurrent chemotherapy endocrine therapy: not specified radiotherapy: no prior or concurrent radiotherapy surgery: no prior or concurrent surgery

Keywords: extensive stage small cell lung cancer
the effect and mechanism of mmp-9 in inducing atherosclerosis

Conditions: Type 2 Diabetes

Summary: the study will assess the serum expression of mmp-9 in normal people, type 2 diabetic patients and type 2 diabetic patients with atherosclerosis.


Eligibility criteria:
inclusion criteria: * volunteer to participate and be able to sign informed consent prior to the trial. * patients with type 2 diabetes, aged 18-60 years old, meeting who1999 diagnostic criteria, have not used any drugs. * the patients have completed carotid ultrasound during hospitalization. exclusion criteria: * patients with any antidiabetic drugs. * impaired liver and kidney function with alt 2.5 times higher than the upper limit of normal value; serum creatinine was 1.3 times higher than the upper limit of normal. * drug abuse and alcohol dependence in the past 5 years. * systemic hormone therapy was used in the last three months. * patients with infection and stress within 4 weeks. * any other obvious conditions or associated diseases determined by the researcher: such as severe cardiopulmonary diseases, endocrine diseases, neurological diseases, tumors and other diseases, other pancreatic diseases, history of mental diseases.
serum biomarkers for portal hypertension in cirrhosis (pan-chess1802)

Conditions: Hypertension, Portal

Summary: this is a prospective, multi-center diagnostic trial conducted at 6 liver centers in china designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hepatic venous pressure gradient in cirrhosis.

hepatic venous pressure gradient (hvpg) is the gold standard for assessing portal pressure, of which the measurement is invasive and therefore not suitable for routine clinical practice. the detection of serum biomarkers is potential for noninvasive diagnosis of portal hypertension in cirrhosis. however, many are still in the exploratory phases of testing and are not yet ready to enter clinical practice. this study prospectively enrolled participants in 6 liver centers (beijing youan hospital, shandong provincial hospital, beijing shijitan hospital, beijing friendship hospital, xingtai people's hospital, and 302 hospital of pla) in china designed to study the correlation between serum biomarkers associated with endothelial dysfunction and immune inflammation and hvpg in cirrhosis.

Eligibility criteria:
inclusion criteria: * age 18-75 years; * confirmed cirrhosis based on histologic examination of liver or combined physical, laboratory, and radiologic findings, including a nodular surface, a coarse texture, and an enlarged caudate lobe of the liver. exclusion criteria: * prior drug therapy (e.g. β-blocker, vasopressin) within two weeks * prior surgeries (e.g. tips, partial splenic embolization/ devascularization, splenectomy, liver transplantation) * non-sinusoidal portal hypertension \& hcc inability to adhere to study procedures * pregnancy or unknown pregnancy status * no informed consent

Keywords: portal hypertension serum biomarker diagnosis
a psm analysis to evaluate electrical pudendal nerve stimulation for ppi

Conditions: Urinary Incontinence Following Surgical Procedure

Summary: the goal of this propensity score matching study is to compare the posttreatment outcomes of post-radical prostatectomy incontinence patients undergoing either electrical pudendal nerve stimulation or pelvic floor muscle training combined with transanal electrical stimulation.

prostate cancer is the predominant form of cancer in older males. radical prostatectomy (rp) is the sole treatment that enhances both overall survival and cancer-specific survival.urinary incontinence remains a major morbidity associated with this procedure, greatly affecting patient satisfaction following rp. extant research underscores the efficacy of pelvic floor muscle training (pfmt) in improving the strength and function of specific pelvic floor muscles, causing hypertrophy of peri-urethral striated muscles, thereby increasing the external mechanical pressure on the urethra. another promising physiotherapy for post-radical prostatectomy incontinence (ppi) is electrical pudendal nerve stimulation (epns). an increasing body of research focuses on comparing continence restoration outcomes between pfmt and various electrical stimulations. however, such studies encompass cases with multiple pathological characteristics, and the reported data might not be considered representative or applicable to other populations due to overlooked confounding factors or selection bias. thus, the investigators intend to conduct a propensity score matching (psm) study aiming to compare the posttreatment outcomes of patients undergoing either epns or pfmt combined with tes, while ensuring a well-balanced control for confounding factor.

Eligibility criteria:
inclusion criteria: * onset of urinary incontinence at least 1 month post-rp * minimum two documented incontinence episodes per week in a 7-day bladder diary * pathological confirmation of no residual cancer post-rp exclusion criteria: * high pathological risk factors (e.g., lymph node metastasis, resection margin involvement, bulky tumors) * preoperative incontinence * prior anticholinergic treatment * urinary tract infection or hematuria * postvoid residual volume exceeding 100 ml (determined by bladder ultrasound) * neurological disorders * urethral stricture